List of Excipients in Branded Drug CHLOROPROCAINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing CHLOROPROCAINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	chloroprocaine hydrochloride	0143-9209	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	chloroprocaine hydrochloride	0143-9209	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	chloroprocaine hydrochloride	0143-9209	SODIUM HYDROXIDE
ProPharma Distribution	chloroprocaine hydrochloride	84549-209	HYDROCHLORIC ACID
ProPharma Distribution	chloroprocaine hydrochloride	84549-209	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in CHLOROPROCAINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	HYDROCHLORIC ACID
2	SODIUM CHLORIDE
2	SODIUM HYDROXIDE

Chloroprocaine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Chloroprocaine hydrochloride is an established, short-acting ester local anesthetic with commercial opportunities in preservative-free spinal, epidural, regional, and ambulatory-surgery products. The strongest product strategy is not a new active-ingredient patent. It is a differentiated injectable platform based on ready-to-use presentation, excipient control, container compatibility, stability, and route-specific regulatory positioning.

The main commercial targets are:

• Preservative-free single-dose vials and ampoules
• Intrathecal products for short surgical procedures
• Ready-to-use epidural and peripheral nerve block presentations
• Lower-waste unit doses for hospitals and ambulatory surgery centers
• Products optimized for obstetric anesthesia and fast recovery
• Regional products supported by local regulatory or 505(b)(2) strategies

Chloroprocaine hydrochloride has limited current small-molecule exclusivity value. Its commercial defensibility depends on manufacturing quality, formulation reliability, route-specific clinical data, device integration, and supply-chain execution.

What is the commercial profile of chloroprocaine hydrochloride?

Chloroprocaine is a rapidly hydrolyzed ester local anesthetic. Its short duration and rapid onset support use where clinicians want reliable anesthesia with comparatively fast motor and sensory recovery.

Attribute	Chloroprocaine hydrochloride
Drug class	Ester local anesthetic
Common concentrations	1%, 2%, and 3% injectable solutions
Common strengths	10, 20, and 30 mg/mL
Key routes	Local infiltration, peripheral nerve block, epidural, caudal; intrathecal use in selected non-U.S. products
Principal advantage	Rapid onset and relatively short duration
Principal limitation	Short duration can limit use in prolonged procedures
Important formulation issue	Preservative and sulfite control
U.S. reference product	Nesacaine and related chloroprocaine hydrochloride injection products
European intrathecal product	Ampres 10 mg/mL
Generic risk	High for conventional injectable presentations
Biosimilar risk	None, because chloroprocaine is a chemically synthesized small molecule

U.S. labeling for chloroprocaine hydrochloride injection covers local anesthesia by infiltration, peripheral and central nerve block, and caudal or epidural block, depending on the specific product and label version.[1] European products such as Ampres are positioned for spinal anesthesia in adults for short lower-limb procedures.[2]

What excipients are used in chloroprocaine hydrochloride products?

The core excipient system is simple. Commercial products generally use water for injection, sodium chloride for tonicity, and hydrochloric acid or sodium hydroxide for pH adjustment. Some multidose or legacy formulations have included antimicrobial preservatives or sulfite-based stabilizing agents.

Representative excipient architecture

Formulation element	Commercial function	Strategic assessment
Water for injection	Vehicle	Standard and low differentiation
Sodium chloride	Tonicity adjustment	Important for intrathecal tolerability
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls solubility, stability, and injection tolerability
Sodium metabisulfite or related sulfite	Antioxidant or stabilizer in selected products	Creates hypersensitivity and labeling complications
Methylparaben or other preservative	Multidose microbial control	Inappropriate for many neuraxial presentations
Nitrogen headspace	Oxygen reduction	Potentially useful where oxidation is a stability concern
Low-extractable container closure	Container compatibility	Relevant for preservative-free and neuraxial products

The commercial direction is toward preservative-free, single-dose presentations. Intrathecal formulations should avoid preservatives and antimicrobial agents because neuraxial exposure creates a higher safety burden than ordinary local infiltration.

Ampres is supplied as a preservative-free 10 mg/mL solution for spinal anesthesia. Its listed excipients include sodium chloride, hydrochloric acid for pH adjustment, and water for injections.[2] U.S. chloroprocaine products have historically included different excipient systems across presentations, including preservative-free and multidose configurations.[1]

What excipient strategy is strongest for a new chloroprocaine product?

A differentiated formulation should use the minimum excipient burden consistent with chemical stability, tonicity, container compatibility, and sterility assurance.

Recommended baseline formulation

A commercially credible intrathecal product would generally use:

• Chloroprocaine hydrochloride at 10 mg/mL
• Sodium chloride for near-isotonicity
• Water for injection
• Hydrochloric acid or sodium hydroxide for pH adjustment
• No antimicrobial preservative
• No sulfite unless stability data establish a clear need
• Single-dose ampoule or vial
• Low-particulate, low-extractable container closure system

A 10 mg/mL presentation is commercially attractive because it aligns with the European Ampres format and permits dose flexibility for short spinal procedures. A 20 mg/mL formulation is more relevant to epidural and regional anesthesia, while 30 mg/mL products can support infiltration or selected nerve-block applications.

Excipient decisions that affect commercial positioning

Preservative-free design

Preservative-free packaging is the strongest broad-market option for neuraxial use. It eliminates concerns associated with methylparaben and reduces the risk that a product developed for infiltration will be unsuitable for spinal anesthesia.

Sulfite-free design

Sulfites can trigger hypersensitivity reactions, particularly in susceptible patients. A sulfite-free product can support cleaner labeling and reduce differentiation barriers in anesthesia formularies. The tradeoff is the need to demonstrate adequate chemical stability without antioxidant protection.

Tonicity control

Intrathecal products require close control of osmolality and pH. Sodium chloride concentration should be established through comparative tolerability and stability work rather than copied mechanically from an existing label. The product should be evaluated for baricity, because glucose-containing hyperbaric formulations could create a different spinal anesthesia profile and a separate clinical development program.

pH control

Chloroprocaine hydrochloride solutions are acidic. A narrow pH range can support stability and reduce injection discomfort, but pH changes may affect precipitation, degradation, and local tolerability. The formulation should establish a defined target range, buffer capacity, and compatibility profile rather than rely on uncontrolled adjustment.

Container closure

Ampoules offer a simple preservative-free presentation with low oxygen ingress. Single-dose polymer vials may improve handling, but extractables, leachables, adsorption, and closure integrity require a stronger data package. Prefilled syringes could reduce preparation time in operating rooms but introduce device, siliconization, plunger, and dose-accuracy issues.

What formulations are protected by chloroprocaine patents?

The principal patent opportunity is formulation and presentation protection, not composition-of-matter protection. Chloroprocaine hydrochloride has been used clinically for decades, so a new patent would need a technically specific distinction.

Potential claim categories include:

1. Preservative-free chloroprocaine hydrochloride at a defined concentration and pH.
2. An intrathecal solution with defined osmolality, impurity limits, and degradation profile.
3. A ready-to-use prefilled syringe or dual-compartment system.
4. A container closure that controls oxygen ingress and limits leachables.
5. A stabilizer-free formulation with a defined shelf life.
6. A specific manufacturing process that reduces chloroprocaine degradation products.
7. A combination of chloroprocaine with a defined adjunct, such as a vasoconstrictor or analgesic.
8. A route-specific method of use for short-duration spinal, epidural, or ambulatory procedures.

The weakest patent strategy would claim only chloroprocaine, sodium chloride, and water at conventional concentrations. Those claims face substantial novelty and obviousness risk because the ingredients and presentation are established in the prior art.

The strongest claims would combine measurable formulation parameters with a demonstrated technical effect, such as improved stability, lower impurity formation, reduced particulate generation, or improved container compatibility.

How strong is the patent estate for chloroprocaine hydrochloride?

The legacy patent estate is weak relative to newer specialty drugs. Chloroprocaine hydrochloride is an old active ingredient, and conventional injectable products are exposed to generic competition.

Patent category	Likely strength	Commercial relevance
Composition of matter	Very low	Historical patents are expired or commercially irrelevant
Conventional injectable composition	Low	Broad claims face prior-art challenges
Preservative-free formulation	Low to moderate	Stronger only with unexpected stability or safety data
Intrathecal presentation	Moderate	Can support route-specific differentiation
Prefilled delivery system	Moderate	Depends on device and human-factors claims
Manufacturing process	Moderate	Useful if impurity control is difficult to reproduce
Method of use	Moderate	Depends on indication, dosing, and clinical evidence
Trade secrets	Moderate to high	Process controls and container compatibility can be difficult to reverse engineer

A product owner should treat patents as one layer of protection. A durable commercial position would combine formulation patents, process know-how, regulatory data, hospital contracts, and reliable supply.

When does chloroprocaine hydrochloride lose exclusivity?

Chloroprocaine hydrochloride has already lost the principal exclusivity associated with a new chemical entity. The relevant commercial question is whether a particular product has remaining regulatory exclusivity, patents, or route-specific protection.

Exclusivity category	Current assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not generally applicable
Pediatric exclusivity	No broad current protection identified
U.S. conventional injectable patent barrier	Limited
European intrathecal product protection	Product-specific and largely dependent on local patent and regulatory records
Biosimilar exclusivity	Not applicable
Generic entry	Feasible for conventional approved presentations

The U.S. Food and Drug Administration’s Orange Book is the controlling source for listed patents and regulatory exclusivity associated with a specific reference-listed product.[3] Conventional chloroprocaine hydrochloride injection products do not have the type of active patent estate associated with recently approved branded specialty drugs.

What is the Orange Book status of chloroprocaine hydrochloride?

The Orange Book should be reviewed at the product level because listing status can vary by strength, dosage form, application number, and sponsor. For a conventional chloroprocaine hydrochloride injection, the key regulatory issues are:

• Whether the reference product has an active listed patent
• Whether the proposed generic matches the listed route and strength
• Whether the formulation is eligible for an abbreviated new drug application
• Whether a different route, concentration, or presentation requires a 505(b)(2) application
• Whether the drug product is currently marketed and listed as therapeutically equivalent

An ANDA is most commercially efficient where the proposed product matches the reference product in active ingredient, dosage form, route, strength, and relevant quality characteristics. An intrathecal product or materially different ready-to-use presentation may require a 505(b)(2) strategy if no suitable U.S. reference product supports the proposed indication and formulation.

What Paragraph IV challenges and litigation affect chloroprocaine?

Chloroprocaine is not associated with a major current U.S. Paragraph IV litigation campaign comparable to high-value branded oncology, immunology, or cardiometabolic products. The limited patent estate reduces the incentive for large-scale Hatch-Waxman litigation.

A generic sponsor should still evaluate:

• Any patents listed against the selected reference product
• Patent certifications required for an ANDA
• Label carve-outs for method-of-use claims
• Formulation patents covering preservative-free or neuraxial products
• Device patents covering prefilled syringes
• Trade-secret risks associated with sterile manufacturing
• State and federal procurement requirements

No broad settlement pattern defines the chloroprocaine market. Commercial disputes are more likely to involve supply, quality, shortage, or contract performance than patent settlements.

What FDA regulatory pathway is most attractive?

Conventional generic injection

An ANDA is the preferred pathway for a product that matches an approved reference injection in strength, route, dosage form, and formulation characteristics. The sponsor benefits from the established safety and efficacy record for the active ingredient.

505(b)(2) formulation

A 505(b)(2) application may be appropriate for:

• Intrathecal use not covered by a suitable U.S. reference product
• A new concentration
• A prefilled syringe
• A novel container closure
• A formulation without sulfite or preservative where the reference formulation differs materially
• A new combination or route-specific presentation

The 505(b)(2) route can support a commercial product with stronger differentiation, but it requires a justification for the clinical bridge and may require additional clinical, compatibility, or safety information.

FDA labeling strategy

A sponsor should separate claims for:

• Local infiltration
• Peripheral nerve block
• Epidural or caudal anesthesia
• Spinal anesthesia
• Ambulatory surgery
• Obstetric procedures

A product designed for intrathecal use should not rely on broad infiltration labeling alone. The formulation, container, sterility controls, dose instructions, and clinical evidence should align with the intended neuraxial route.

What commercial opportunities exist for chloroprocaine hydrochloride?

Ambulatory surgery

Short procedures are the clearest opportunity. Hospitals and surgery centers may value rapid recovery, reduced motor block duration, and predictable discharge timing.

A ready-to-use single-dose product can compete on operating-room workflow rather than price alone. The commercial package should include clear dosage guidance, barcoding, tamper evidence, and minimal preparation steps.

Obstetric anesthesia

Chloroprocaine can be relevant to urgent epidural or spinal anesthesia where rapid onset is important. A preservative-free, low-particulate product with reliable onset and short recovery could support obstetric use, subject to local labeling and clinical evidence.

Hospital formulary conversion

A generic or branded-generic product can win share by offering:

• Lower unit cost
• Reduced vial waste
• Stable supply
• Preservative-free packaging
• Concentration options aligned with hospital protocols
• Clear differentiation between neuraxial and non-neuraxial presentations

Regional anesthesia

A 20 mg/mL product can target peripheral nerve blocks and epidural use. A 10 mg/mL spinal product should remain operationally distinct to prevent concentration errors.

Combination products

Combination products with epinephrine, clonidine, dexmedetomidine, or opioids could extend duration or alter block quality. They also create substantial regulatory, compatibility, dosing, and safety complexity. A combination product should be pursued only where clinical utility is clear and the formulation demonstrates a measurable advantage over separate administration.

How does chloroprocaine compare with competing local anesthetics?

Drug	Onset	Duration	Main commercial position
Chloroprocaine	Rapid	Short	Fast recovery and short procedures
Lidocaine	Rapid	Short to intermediate	Broad, low-cost use
Mepivacaine	Moderate to rapid	Intermediate	Peripheral and dental anesthesia
Bupivacaine	Slower	Long	Prolonged analgesia and nerve blocks
Ropivacaine	Moderate	Long	Regional anesthesia with branded and generic competition
Prilocaine	Moderate	Intermediate	Local and selected regional applications

Chloroprocaine is unlikely to displace long-acting bupivacaine or ropivacaine in prolonged postoperative analgesia. Its strongest position is where short duration, rapid recovery, and predictable operating-room turnover matter.

What manufacturing and intellectual-property barriers exist?

The active ingredient is not the primary manufacturing barrier. The more important barriers are sterile injectable production, impurity control, container compatibility, and consistent release testing.

Key manufacturing controls include:

• Assay and related-substance testing
• Control of hydrolysis and oxidation products
• Sterility and bacterial endotoxin limits
• Particulate matter
• Osmolality
• pH
• Fill-volume accuracy
• Container closure integrity
• Extractables and leachables
• Stability under refrigerated and room-temperature conditions

The product owner should retain process knowledge covering solution preparation, nitrogen management if used, filtration, filling, terminal sterilization where feasible, and closure performance. These controls may produce more practical protection than a broad formulation patent.

Which companies are challenging or competing with chloroprocaine products?

Competition comes from several groups:

1. Established manufacturers of chloroprocaine hydrochloride injection.
2. Generic injectable companies supplying hospitals.
3. European suppliers of preservative-free intrathecal products.
4. Manufacturers of lidocaine, mepivacaine, bupivacaine, and ropivacaine.
5. Contract development and manufacturing organizations with sterile fill-finish capacity.

The competitive field is fragmented. No single company controls the underlying active ingredient. Market share is likely to depend on formulary access, shortage performance, pricing, and the ability to supply multiple concentrations without medication-use confusion.

What licensing deals are commercially realistic?

Licensing value is more likely to arise from assets surrounding chloroprocaine than from the active ingredient itself.

Potential transaction structures include:

• Regional rights to an intrathecal formulation
• Co-development of a prefilled syringe
• Contract manufacturing with minimum-volume commitments
• Licensing of a sterile injectable process
• Hospital-channel distribution rights
• Combination-product development with a device company
• Out-licensing of a 505(b)(2) formulation package

A conventional generic chloroprocaine product would generally command limited royalty value. A differentiated neuraxial product with clinical data, regulatory clearance, and scalable manufacturing could support a more attractive regional licensing transaction.

What revenue exposure and generic launch scenarios exist?

Chloroprocaine is a smaller market than long-acting regional anesthetics. Revenue exposure is concentrated in hospitals, ambulatory surgery centers, anesthesia groups, and distributors.

Generic launch scenario

A conventional ANDA product would likely face rapid price competition if multiple suppliers enter. The launch must therefore emphasize supply reliability, manufacturing quality, and contract access.

Differentiated branded-generic scenario

A preservative-free, single-dose or prefilled product could retain a premium if it reduces preparation time and medication waste. The premium would need to be supported by purchasing data, operating-room workflow benefits, or documented shortage resilience.

Specialty intrathecal scenario

An intrathecal product can support higher pricing than a conventional multidose injection if it has a route-specific label, validated packaging, and reliable availability. The opportunity remains limited by procedure volume and competition from established spinal anesthetics.

Key Takeaways

• Chloroprocaine hydrochloride is an old small-molecule local anesthetic with no meaningful new-chemical-entity exclusivity.
• The strongest excipient strategy is preservative-free, sulfite-free where feasible, single-dose, and optimized for the intended route.
• Sodium chloride, water for injection, and controlled pH adjustment are the most commercially defensible baseline excipients.
• Intrathecal products require tighter control of osmolality, pH, particulate matter, sterility, and container compatibility.
• Conventional injectable products face high generic competition.
• A 505(b)(2) strategy may be preferable for a new intrathecal, prefilled, or materially differentiated presentation.
• Formulation patents are possible but should rely on measurable technical effects rather than routine excipient combinations.
• The highest-value commercial opportunities are ambulatory surgery, short spinal procedures, obstetric anesthesia, and ready-to-use hospital presentations.
• Manufacturing quality, supply reliability, and route-specific labeling are likely to create more practical value than broad patent claims.
• Biosimilar competition is irrelevant because chloroprocaine hydrochloride is a small molecule.

FAQs

Is chloroprocaine hydrochloride preservative-free?

Some commercial products are preservative-free, while legacy or multidose products may use preservatives or sulfite-based excipients. The label for the specific strength and presentation controls the answer.

Can chloroprocaine hydrochloride be used intrathecally?

Yes, preservative-free chloroprocaine products are used for spinal anesthesia in selected jurisdictions, including the European Ampres product. U.S. use depends on the approved product labeling and regulatory pathway.

What is the best concentration for a chloroprocaine spinal product?

A 10 mg/mL presentation is commercially established for spinal anesthesia in Europe. The appropriate concentration depends on the intended dose range, baricity, procedure duration, and regulatory evidence.

Does chloroprocaine hydrochloride require a new patent to be commercially viable?

No. A conventional generic can compete without a new patent, but its commercial position will be vulnerable to price erosion. A formulation, device, process, or method-of-use patent can improve defensibility.

Is chloroprocaine hydrochloride vulnerable to shortage-driven market opportunities?

Yes. Sterile injectable shortages can create temporary opportunities for manufacturers with validated capacity, reliable fill-finish operations, and regulatory-compliant supply. The opportunity is operational rather than based on active-ingredient exclusivity.

References

1. U.S. Food and Drug Administration. (n.d.). Nesacaine and chloroprocaine hydrochloride injection prescribing information. FDA and DailyMed labeling records.

2. European Medicines Agency. (n.d.). Ampres 10 mg/mL solution for injection: Product information. European Medicines Agency.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.